Evogene traded at 253.40 this Thursday June 30th, decreasing 7.60 or 2.91 percent since the previous trading session. Looking back, over the last four weeks, Evogene lost 15.51 percent. Over the last 12 months, its price fell by 77.58 percent. Looking ahead, we forecast Evogene to be priced at 256.87 by the end of this quarter and at 235.82 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Evogene 253.40 -7.60 -2.91% -77.58%

Indexes Price Day Year
TA-125 1884 -42.29 -2.20% 6.70%

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.